Dietitian support may lower CVD risk
The New England region has one of the highest rates of cardiovascular disease in New South Wales.
Are you looking for a reason to reconnect with patients who may have put off their yearly check-ups?
The HealthyRHearts research project will ask you to screen your patient lists for people aged 45-70 years who need to come in for a heart health assessment. It is a randomised controlled trial, with the intervention group receiving up to five telehealth dietetic consults from rural dietitians, specially upskilled for the study. The usual care group will get detailed feedback about their nutrition. Both groups will be managed concurrently by their GPs, with study information available to doctors.
Interested in the project? Full details and GP responsibilities can be obtained from the HealthyRHearts research team via email: HealthyRHearts@newcastle.edu.au , or phone 02 4921 6259 for further information.
The first COVID-19 vaccine developed in the Southern Hemisphere, which was developed by Adelaide-based company Vaxine Pty Ltd uses recombinant protein technology. The new vaccine is being trialed as a booster by the University of New England’s Medical Centre.
While already approved overseas, the current trial will provide important data on the vaccine’s use as a booster. It is hoped this Australian trial will accelerate local access to this locally designed protein-based vaccine which uses an insect-cell manufacturing approach already used for commercial vaccines against influenza and human papilloma virus.
UNE’s Medical Centre is one of only two trial sites in NSW. The aim is to recruit up to 200 participants, who will have a single booster vaccine dose and just need to provide before-and-after blood tests for measurement of antibody levels to see their response to the vaccine.
Anyone interested in participating in the trial or requesting further information can contact firstname.lastname@example.org
For enquiries relating to the UNE Medical Centre trials, contact Dr Joe Turner via Centre reception on 02 6773 2916.
For enquiries relating to the COVID-19 vaccine development and technology, contact Sharen Pringle from Vaxine on 0437 033 400